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Abstract
Parkinson’s disease (PD) is characterized by resting tremor, rigidity, and bradykinesia.
Dopaminergic medications treat motor symptoms, but have complex effects on cognition,
including impulse control. Impulsivity is multifaceted in nature. Motor impulsivity involves
inability to withhold prepotent, automatic responses whereas cognitive impulsivity refers to
increased risk-taking and reward-seeking. We anticipated that dopaminergic therapy would
decrease motor impulsivity. We employed the Go/No-go paradigm to assess motor
impulsivity. PD patients were tested on and off their dopaminergic medication. PD patients
on medication had a significantly higher proportion of Go Timeouts (i.e., Go responses not
completed by the 750 millisecond deadline) compared to off medication (p=0.01). We
interpret that dopaminergic therapy induces more conservative responding (i.e., decreased
motor impulsivity) in PD patients. This contrasts with the widely-recognized notion of
dopaminergic therapy increasing cognitive impulsivity and risk of impulse control disorders.
Understanding the nuanced effects of dopaminergic treatment in PD will inform clinical
decisions.
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Chapter 1 : Introduction
A version of subsections 1.4.2 and 1.5 of this chapter has been published (Yang, Lauzon,
Seergobin, & MacDonald, 2018).

1.1 Parkinson’s disease
1.1.1 Symptomatology
Parkinson’s disease (PD) is a progressive and incurable neurodegenerative disorder. Risk
of PD increases with age; prevalence of the disease worldwide is 428 per 100 000
individuals aged 60-69, 1087 per 100 000 individuals aged 70-79, and 1903 per 100 000
individuals aged 80+ (Pringsheim, Jette, Frolkis, & Steeves, 2014). It is the
neurodegenerative disorder with the second highest prevalence, behind only Alzheimer’s
disease (de Lau & Breteler, 2006). Symptoms of PD typically arise in older age, with
average PD age-of-onset of 65 years old, with a smaller number of early-onset PD
patients (Connolly & Lang, 2014). The disease primarily affects motor functioning, with
the cardinal symptoms of PD being resting tremor, rigidity, and bradykinesia (Jankovic,
2008). Resting tremor refers to a tremor in various areas of the body, commonly the
limbs, that occurs at rest but dissipates or even disappears with the assumption of posture
or with deliberate movement (Jankovic, 2008). Patients with PD often experience a
phenomenon called cogwheel rigidity in the upper limbs (Jankovic, 2008). When the
forearm is passively extended at the elbow, intermittent resistance can be felt that
resembles ratcheting, or ‘cogwheeling’. Bradykinesia is the presence of slowed
movements (Jankovic, 2008). A unique feature of PD symptomology is unilateral onset
of motor symptoms and asymmetry of motor impairments that persist throughout the
disease course (Dickson, 2012). The asymmetry of symptoms is not observed in multiple
systems atrophy and progressive supranuclear palsy that are diseases under the
parkinsonism umbrella, helping with diagnosis, though corticobasal ganglionic
degeneration and Lewy body dementia can present asymmetrically (Dickson, 2012). In
addition to motor symptoms, PD diagnosis is commonly associated with subtle cognitive
dysfunction that might not necessarily reduce daily function (Aarsland, Brønnick, &
Fladby, 2011; Litvan et al., 2012). As PD progresses, motor function becomes
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increasingly impaired and the risk of developing motor complications such as dyskinesias
increases (Coelho & Ferreira, 2012; Kalia & Lang, 2015). In late stage PD, patients also
experience disruptions in cognition, gait/balance, and autonomic function (Coelho &
Ferreira, 2012; Kalia & Lang, 2015). Unfortunately, there is no cure for Parkinson’s
disease at present.

1.1.2 Dopaminergic system
The principal neurotransmitter system impacted by PD is the dopaminergic system. The
main dopamine-producing neurons are found in the substantia nigra pars compacta (SNc)
and the ventral tegmental area (VTA), both located in the midbrain. The striatum receives
significant investment of dopaminergic projections and is the input region of the basal
ganglia, a collection of sub-cortical nuclei (Meyer & Quenzer, 2013). The striatum is
commonly conceptually divided into dorsal and ventral components (i.e., DS and VS,
respectively) based on differences in function, dopaminergic inputs, and glutamatergic
projections from cortex (Voorn, Vanderschuren, Groenewegen, Robbins, & Pennartz,
2004). DS is comprised of the bulk of the caudate nuclei and putamen, whereas VS
includes the nucleus accumbens (NAcc) and the most ventral aspects of the caudate and
putamen (Voorn et al., 2004). The striatum is also divided histochemically into
striosomes, which are labyrinth-like structures containing 10-15% of striatal volume, and
the matrix, which comprises the remaining majority of striatal volume (Brimblecombe &
Cragg, 2017). The dopaminergic system consists of three primary pathways (see Figure
1): the nigrostriatal, mesolimbic, and mesocortical pathways (Meyer & Quenzer, 2013).
The nigrostriatal pathway originates in the SNc and projects to the DS (Meyer &
Quenzer, 2013). The mesolimbic and mesocortical pathways originate in the VTA and
innervate a) the VS, hippocampus, and mediotemporal regions, versus b) the prefrontal
cortex, respectively (Meyer & Quenzer, 2013).
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Figure 1. Major dopaminergic brain regions and dopamine pathways in the brain.
Ernst, M. & Luciana, M. (2015). Neuroimaging of the dopamine/reward system in adolescent drug use.
CNS Spectrums, 20(4), 427-441. Reproduced with permission. © Cambridge University Press 2015.

Dopamine secreted by the SNc and VTA bind to and activate dopamine receptors located
on medium spiny neurons (MSNs) throughout the striosomes and matrix of the striatum
(Bolam, Hanley, Booth, & Bevan, 2000). Dopamine receptors, which are G-protein
coupled receptors, are loosely divided into D1-like and D2-like receptors. D1-like
receptors (i.e., D1, D5) couple to Gs stimulatory G proteins to induce downstream
activation, whereas D2-like receptors (i.e., D2, D3, D4) cause inhibition by coupling to
Gi inhibitory G proteins (Jaber, Robinson, Missale, & Caron, 1996). D1-like receptors are
largely found within striosome structures and D2-like receptors are richly expressed in
the striatal matrix (Brimblecombe & Cragg, 2017). The two types of dopamine receptors
contribute to the direct and indirect pathways of the basal ganglia (see Figure 2).
Engagement of the direct pathway results in overall increased activation of the cortical
region to which the striatal segment projects (Purves et al., 2001). The indirect pathway
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dampens the activation of the direct pathway through inhibitory connections to the
external segment of the globus pallidus and subthalamic nucleus (Purves et al., 2001). As
such, engagement of the indirect pathway leads to decreased thalamic and cortical
activation (Purves et al., 2001). Collectively, these two pathways constitute a fine-tuned
and highly-precise system for coordinating complex cortical networks that underlies
functions such as motor movements.

Figure 2. Direct and indirect pathways of the basal ganglia.
Leisman, G., Melillo, R., & Carrick, F. R. (2012). Clinical motor and cognitive neurobehavioral
relationships in the basal ganglia. In C. Bauer (Ed.), Basal ganglia - An integrative view (pp. 1-30).
London, UK: IntechOpen Limited. Reproduced with permission. © 2012 Leisman et al., licensee InTech.

DA synaptic signaling is regulated by the activity of dopamine transporter (DAT), which
engages in the reuptake of dopamine back into the presynaptic nerve terminal or into
surrounding glia (Purves et al., 2001). DAT is a sodium-dependent transporter and can be
located on presynaptic MSNs throughout the striatum (Chen & Reith, 2000; van Dyck et
al., 2002). After reuptake, dopamine is metabolized by catechol O-methyltransferase
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(COMT), which is a cytoplasmic enzyme, and monoamine oxidase (MAO), which is
located on the outer mitochondrial membrane (Purves et al., 2001). These dopaminedegrading enzymes can be found in striatal neurons as well as associated glial cells
(Purves et al., 2001).

1.1.3 PD neuropathology
The central neuropathology in PD is the degradation of the SNc, a dopamine-producing
subregion of the SN (Dauer & Przedborski, 2003). This neurodegeneration results in
disruption to the nigrostriatal pathway and dopamine deficiency in the DS (Meyer &
Quenzer, 2013), giving rise to the hallmark motor symptoms of PD (Dickson et al.,
2009). In normal brains, slices of the midbrain show a visible dark band along the SNc
(see Figure 3A). This is attributed to neuromelanin pigmentation found in dopaminergic
neurons of the SNc (Dauer & Przedborski, 2003). The nigrostriatal pathway is intact and
appropriately supplies the caudate and putamen with dopamine. However, the
pigmentation along the SNc ridge in midbrain slices of PD patients is greatly reduced
because of the loss of dopaminergic neurons and the associated production of
neuromelanin (see Figure 3B). The degeneration of SNc neurons is extensive; by the
time PD patients exhibit clinical symptoms, approximately 60% of neurons in the SNc
have already been lost and dopamine supply to the putamen is reduced by approximately
80% (Dauer & Przedborski, 2003). Neurodegeneration can also be detected in other brain
regions in PD, including the locus ceruleus, amygdala, and hypothalamus (Dickson,
2012).
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Figure 3. Neuropathology of PD.
A) Schematic of a normal brain. The SNc is clearly visible as a darker pigmented line in the midbrain due
to neuromelanin produced in dopaminergic neurons. The nigrostriatal pathway is intact and supplies
dopamine to the caudate and putamen. B) Schematic of a PD brain. Decreased neuromelanin pigmentation
in SNc is observed due to the marked loss of dopaminergic neurons. The nigrostriatal pathway degenerates.
Dauer, W. & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39(6), 889909. Reproduced with permission. © 2003 by Cell Press.

Another characteristic pathology of PD is the formation of α-synuclein protein aggregates
called Lewy bodies (Schulz-Schaeffer, 2010; Wakabayashi et al., 2013). Research has
suggested that Lewy bodies interfere with dopamine release from pre-synaptic neurons of
the SN (Schulz-Schaeffer, 2010; Wakabayashi et al., 2013). Lewy pathology is
hypothesized to progress along a predictable temporal and spatial pattern, giving rise to
the Braak staging system for the clinical course of PD (Braak et al., 2003). Studies in PD
and dementia patients have also linked Lewy body pathology to mild cognitive
impairment and dementia (Irwin et al., 2012; Kempster, O’Sullivan, Holton, Revesz, &
Lees, 2010; Selikhova et al., 2009).

8

Aside from a small percentage of cases for which the risk of developing PD is genetically
inherited, the vast majority of PD is of idiopathic origin (Dauer & Przedborski, 2003).
Research has suggested the influence of PD-related genes, environmental neurotoxins,
and endogenous toxins generated by altered metabolism as potential factors contributing
to the onset of PD neurodegeneration (Dauer & Przedborski, 2003). However, no single
explanatory model exists for the etiology of PD. The characteristic motor symptoms of
PD are largely attributed to the loss of dopaminergic innervation to the DS as a result of
neurodegeneration of the SNc (Jankovic, 2008). However, the integrity of the VTA is
largely intact until late stages of disease progression (Kish, Shannak, & Hornykiewicz,
1988; Rakshi et al., 1999). As a result, VTA dopamine production and downstream VS
functioning is relatively spared in PD (Kish et al., 1988; Rakshi et al., 1999).

1.2 Dopaminergic medications
1.2.1 L-dopa
Although no therapies to stop or slow down PD disease progression exist,
pharmacological treatments can alleviate motor symptoms. The most commonly used
dopaminergic medication is L-3,4-dihydroxyphenylalanine (L-dopa or levodopa;
Connolly & Lang, 2014). L-dopa is taken orally and acts as a precursor for dopamine
production (Lang & Lees, 2002). Because L-dopa is subject to degradation in the
bloodstream, it is almost always co-administered with carbidopa, a dopamine
decarboxylase inhibitor that prevents premature degradation. Once L-dopa crosses the
blood-brain barrier, it is metabolized into dopamine by the enzyme aromatic amino acid
decarboxylase (Meyer & Quenzer, 2013). As such, treating with L-dopa acts as an
exogenous source of dopamine for PD patients, who are unable to produce the required
concentrations from the SNc.
Although L-dopa is initially effective at improving motor functioning, approximately
50% of PD patients on L-dopa therapy begin to experience motor fluctuations within 4-6
years (Ahlskog & Muenter, 2001). Dyskinesia, which can be described as involuntary
non-rhythmic motions, is one such motor disruption (Connolly & Lang, 2014). Because
dyskinesia results in unintended jerky or swaying movements, PD patients can experience
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substantial social embarrassment and stigma (Connolly & Lang, 2014). The onset of
dyskinesia is strongly correlated with the peak in L-dopa concentration (Obeso, Olanow,
& Nutt, 2000). Unfortunately, because PD patients often take larger and more closelyspaced doses of L-dopa as the disease progresses, the risk of dyskinesia increases (Obeso
et al., 2000). Late PD patients also commonly experience on-off fluctuations, which
involve a rapid loss of motor functioning as the L-dopa wears off (Blandini & Armentero,
2014). The presence of these motor disturbances has been found to correlate with the
duration and dose of L-dopa therapy (Ahlskog & Muenter, 2001). As such, it is
preferable to avoid the initiation of L-dopa treatment if possible, within the limits of
patient comfort and quality of life (Ahlskog & Muenter, 2001).

1.2.2 Dopamine agonists
DA agonists, another common class of dopaminergic treatment, bind directly to
dopamine receptors and upregulate post-synaptic receptor activity (Blandini &
Armentero, 2014). Dopamine agonists can be divided into the first generation ergot-based
agonists (e.g., bromocriptine, cabergoline, pergolide), and newer non-ergot agonists (e.g.,
pramipexole and ropinirole; Borovac, 2016). Both classes of dopamine agonists target D2
receptors. However, one of the issues with ergot-based agonists is that they do not bind to
D2 receptors with high affinity (Borovac, 2016). Ergotine agonists can bind with D1
receptors, as well as serotonergic and adrenergic receptors, causing a range of adverse
side effects (Borovac, 2016). In particular, ergot-based dopamine agonists have been
associated with an increased risk of cardiac and valvular fibrosis (Blandini & Armentero,
2014). The newer non-ergot agonists have higher affinity with D2 receptors and elicit
fewer adverse side effects (Borovac, 2016). For these reasons, non-ergot dopamine
agonists such as pramipexole and ropinirole are much more commonly prescribed for the
treatment of PD (Connolly & Lang, 2014). When dopamine agonists were first
introduced for the treatment of PD, they were incorporated into medication regimens as
an adjunct therapy for L-dopa (Fischer, 1995). With the addition of dopamine agonists,
PD patients required 20-30% less L-dopa, decreasing the risk and severity of L-doparelated motor complications (Brooks, 2000). Dopamine agonists are now commonly used
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as a monotherapy, especially for early-onset PD patients, for whom it is advisable to
delay the initiation of L-dopa treatment (Brooks, 2000).
However, dopamine agonists in particular have been linked to the development of
impulse control disorders (ICDs; see Section 1.4 for more details). Further, age has been
found to be negatively correlated with ICD risk (Voon et al., 2007; Weintraub et al.,
2010). Voon and colleagues (2007) found that PD patients with history of pathological
gambling were significantly younger than a control group of non-ICD PD patients. In a
large-scale study of 3090 PD patients, younger age was also identified as a risk factor for
developing an ICD, along with the use of dopamine agonist medication (Weintraub et al.,
2010). As such, it is crucial to assess pre-existing risk of ICD before incorporating a
dopamine agonist into a patient’s medication regimen. Each medication is associated with
unique advantages and disadvantages; the development of a medication regimen that is
best suited for each individual PD patient is often a delicate balancing act between
different therapies.

1.3 Dopamine overdose hypothesis
L-dopa and dopamine agonists as described above are prescribed by physicians to remedy
the motor symptoms of PD. However, because of the asymmetrical nature of SNc and
VTA degradation, treatment with dopaminergic therapies affect DS- and VS-mediated
functions differently (Vaillancourt, Schonfeld, Kwak, Bohnen, & Seidler, 2013).
Although dopaminergic treatment has clear benefits for motor ability, its impact on
cognitive functioning is more complex. Dopaminergic therapy has been shown to
improve some cognitive functions but impair others (MacDonald & Monchi, 2011). The
dopamine overdose hypothesis has been proposed to explain this phenomenon
(Vaillancourt et al., 2013).
The dopamine overdose hypothesis originates from research in the late 1980s showing
that the treatment of L-dopa in PD patients can benefit or worsen aspects of frontal
cognitive function (Gotham, Brown, & Marsden, 1986, 1988). Since then, the hypothesis
has gained support from behavioural, neuroimaging, and animal research (MacDonald &
Monchi, 2011). The dopamine overdose hypothesis posits that as dopaminergic
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treatments remediate dopamine insufficiency in the DS, an unintentional overdosing of
the VS occurs and other brain regions receiving dopamine from the VTA, which
maintains relatively normal dopamine levels in PD (Vaillancourt et al., 2013).
Functioning of dopaminergic structures has been modelled in the shape of an inverse-U
curve (see Figure 4). Because the DS is dopamine-deficient in PD, it falls left of peak
performance on the inverse-U curve (Vaillancourt et al., 2013). Functions mediated by
VS as well as by prefrontal and limbic cortex are already at peak on the curve because of
intact VTA dopamine production (Kish et al., 1988; Rakshi et al., 1999). Dopaminergic
medication brings DS functioning to a maximal level, but also pushes VS functioning
past the peak to a lower level of function (Vaillancourt et al., 2013). This phenomenon
can be influenced by disease duration, medication dosage, and genetic factors (Cools,
2006).
In accordance with the dopamine overdose hypothesis, cognitive functions that have been
shown to be DS-mediated through neuroimaging and lesion studies largely improve with
dopaminergic medication. These include selective attention, memory retrieval, decision
making, task switching, and particularly inhibiting prepotent or habitual responding
(MacDonald & Monchi, 2011). Conversely, functions that are suggested by
neuroimaging to be VS-mediated typically show a worsening of performance with the
addition of dopaminergic treatment. Implicit and explicit learning, reversal learning,
orienting to stimuli, and cognitive impulsivity all show this expected pattern (MacDonald
& Monchi, 2011). Behavioural studies commonly use these established patterns of
behaviour to theorize the neurological basis of the cognitive function of interest (i.e., DSversus VTA-innervated brain region- mediated; MacDonald & Monchi, 2011).
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Figure 4. The dopamine overdose hypothesis.
If baseline dopamine level is low (shown in red), L-dopa will improve performance. However, if baseline
dopamine level is high (shown in blue), L-dopa will worsen performance by pushing performance past the
maximal level. Vaillancourt, D. E., Schonfeld, D., Kwak, Y., Bohnen, N. I., & Seidler, R. (2013).
Dopamine overdose hypothesis: Evidence and clinical implications. Movement Disorders, 28(14), 19201929. Reproduced with permission. © 2017 John Wiley & Sons, Inc.

1.3.1 Mechanisms
The mechanisms for the dopamine overdose hypothesis are rooted in the unique
neurobiological properties of the DS and VS. The DS contains MSNs with more and
denser dendritic projections that allow for rapid maximal response to dopamine
(Wickens, Budd, Hyland, & Arbuthnott, 2007; Zhang et al., 2009). The DS is also rich in
DAT, allowing for rapid synaptic clearance, resulting in dopamine activation patterns in
this region that summate and rapidly decay (MacDonald & Monchi, 2011). When
dopaminergic therapies are administered in PD, this maximal rapid receptor stimulation is
remediated in the dopamine-deficient DS (MacDonald & Monchi, 2011). Because of the
characteristics of DS dopamine signaling, the DS has been theorized to summate inputs
from many sources and mediate binary responding (i.e., engage or suppress) between
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alternative choices (MacDonald & Monchi, 2011). As such, the DS has been linked to
decision-making and selection between stimuli (MacDonald & Monchi, 2011).
Compared to DS neuroanatomy, the VS is comprised of smaller MSNs with fewer and
sparser dendritic projections (Wickens et al., 2007). Lower DAT concentration can also
be found throughout the VS, leading to prolonged synaptic presence of dopamine
(Wickens et al., 2007). These properties contribute to dopamine signaling patterns in the
VS that are slower, graded and variable in intensity, and longer lasting (Zhang et al.,
2009). These properties allow the VS to be a suitable mediator of generating associations
between stimuli and rewards across time, as well processing response outcomes in
probabilistic events (MacDonald & Monchi, 2011). Indeed, the presence of reciprocal
connections between VS and memory- and association-related regions of the brain such
as the anterior cingulate cortex, orbitofrontal cortex, and hippocampus, support the
interpretation of VS involvement in learning and memory (MacDonald & Monchi, 2011).
Whereas dopaminergic treatment enhances rapid absolute dopamine signaling in the DS,
excess dopamine concentration disrupts delicate phasic dopaminergic signaling patterns
in the VS, leading to impairments in VS-mediated cognitive functions such as associative
learning (MacDonald & Monchi, 2011).

1.4 Impulsivity
The influence of dopamine on impulse control has been a point of scientific interest since
the idea of dopamine’s role in cognition was recognized. One of the earliest accounts of
impaired impulse control in PD originated from a group of German researchers who
presented two case studies of PD patients being treated with dopaminergic therapies who
experienced strong sexual urges and engaged in sexual delinquency (Berger, Mehrhoff,
Beier, & Meinck, 2003). Driver-Dunckley, Samanta, and Stacy (2003) then described
nine PD patients who developed pathological gambling after beginning dopamine agonist
treatment. The following year, Avanzi, Uber, and Bonfà (2004) published a paper
discussing two cases of pathological gambling in PD patients who were taking
dopaminergic replacement therapy. These papers paved the way for the popularization of
PD-impulse control research in subsequent years (Dodd et al., 2005; Silver, 2005;
Stocchi, 2005; Weintraub et al., 2006).
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In the present-day literature, it is commonly known that dopaminergic treatment, in
particular dopamine agonists, increase risk of developing ICDs. Weintraub and
colleagues (2010) in a large-scale study of 3090 PD patients found that as many as 13.6%
of PD patients experienced one or more ICD behavioural symptoms. These problem
behaviours include pathological gambling, hypersexuality and sex addiction, compulsive
buying, and binge eating disorder (Weintraub et al., 2010). ICDs often present with
similar characteristics as drug addiction, such as tolerance effects and/or withdrawal
symptoms (Leeman & Potenza, 2012). Neuroimaging studies in PD patients with and
without ICD(s) have found increased dopamine release to the VS in PD subjects with
concurrent ICD compared to PD patients without ICD (O’Sullivan et al., 2011; Steeves et
al., 2009; Wu et al., 2015), demonstrating a clear link between the presence of ICDs and
dysfunctional mesolimbic activation.
DA agonists were identified as a significant ICD risk factor, having been associated with
almost three-fold increased odds of developing one or more ICDs, compared to PD
patients not treated with dopamine agonists (Weintraub et al., 2010). However, L-dopa
use can also precipitate ICDs, and in fact PD patients with ICDs tend to require higher Ldopa dosage (Voon, Sohr, et al., 2010). It is standard practice for neurologists to warn PD
patients of the risk of developing ICDs and to be vigilant for new ICD behaviours when
starting dopaminergic treatment and especially dopamine agonist therapy (Connolly &
Lang, 2014). This is particularly critical for PD patients who already have underlying
obsessive-compulsive tendencies, addictive personalities, or history of addiction (Weiss
& Marsh, 2012). For these individuals, dopamine agonist treatment might be advised
against altogether, despite potential motor benefits. ICDs can have serious ramifications
for quality of life. Anecdotal accounts have been described of PD patients who have
gambled their life savings away and lost their home in the process, engaged in sexually
deviant behaviours and ruined their marriage, or developed obesity due to continued
binge-eating. These dangerous real-life ramifications highlight the importance of
maintaining appropriate impulse control abilities for everyday function.
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1.4.1 Multifaceted nature of impulsivity
Although it is tempting to view impulsivity as a single concept for the sake of simplicity,
impulsivity has been increasingly understood as a multifaceted construct (Antonelli, Ray,
& Strafella, 2011). Nombela, Rittman, Robbins, and Rowe (2014) used a factor analysis
approach to compare different behavioural measures under the umbrella of “impulsivity”.
They identified four main impulsivity factors: 1) response conflict, interference effects,
and self-reported impulsivity; 2) motor inhibitory control; 3) time estimation and delay
aversion; and 4) temporal discounting and reflection impulsivity (Nombela et al., 2014).
Another research group has suggested a simpler model of motivational/cognitive
impulsivity and performance/motor impulsivity (Antonelli et al., 2011). Cognitive
impulsivity corresponds with behaviours including risky decision-making, increased
propensity towards reward-seeking, and impoverished feedback-learning (Antonelli et al.,
2011). Cognitive impulsivity is purportedly the underlying factor for the development of
ICDs (Claassen et al., 2011). On the other hand, motor impulsivity refers to the inability
to withhold automatic and pre-potent responses and impaired ability to cancel responses
that have already been planned or initiated (Antonelli et al., 2011). Motor impulsivity can
also impact quality of life, as it has been linked with greater risk of falls (Wylie et al.,
2012). Collectively, cognitive and motor impulsivity comprise aspects of cognition that
are of clinical relevance in PD.

1.4.1.1 Cognitive impulsivity
Because of the link between cognitive impulsivity and ICDs, cognitive impulsivity in PD
has been a point of clinical interest for researchers. Antonelli and colleagues (2011)
describe cognitive impulsivity as a complex psychological domain comprised of altered
decision-making,

elevated

risk-taking

under

stable

or

unknown

probabilistic

contingencies, poor ability to delay rewards in lieu of smaller immediate rewards, and
impaired reward and reversal learning. Using tasks aimed at assessing cognitive
impulsivity such as the Iowa Gambling Task, Cambridge Gambling Task, and Risk Task,
imaging studies have implicated mesolimbic and mesocortical structures including the
VTA, NAcc, amygdala, and inferior, orbital, and dorsolateral prefrontal cortices (Hsu,
Bhatt, Adolphs, Tranel, & Camerer, 2005; Rogers et al., 1999; Verdejo-García &
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Bechara, 2009). The same regions have been implicated in PD patients with concurrent
pathological gambling (van Eimeren et al., 2010).
Another popular behavioural paradigm for assessing cognitive impulsivity is the Balloon
Analogue Risk Task (BART; Lejuez et al., 2002). This task, which is typically
administered in the form of a computer program, consists of a series of balloons that the
participant is presented with. For each trial, the participant can choose to pump the
balloon larger with air by making a keypress response. With each pump, an amount of
money is accrued for the balloon. Once the participant is satisfied, he/she can press a key
to collect the accrued money into a permanent bank and move onto the next trial.
However, if the balloon is over-pumped, the balloon pops and all money is lost for that
trial. Typically, each balloon has a randomly-determined pop point as to avoid systematic
learned responses. This task is a measure of risk-taking (i.e., how far participants are
willing to pump up each balloon before collecting at the risk of the balloon popping). The
BART has shown sound construct validity; it correlates with other measures of sensation
seeking, impulsivity, and self-reported history of addiction (Lejuez et al., 2002).
Functional magnetic resonance imaging (MRI) has supported the involvement of the
mesolimbic and mesocortical pathways in BART performance, with participants showing
increased neural activation in the VTA, striatum including the NAcc, insular cortex,
anterior cingulate cortex, and dorsolateral prefrontal cortex during the task (Rao,
Korczykowski, Pluta, Hoang, & Detre, 2008).
The BART has been implemented in the PD population to examine differences between
PD patients and healthy controls (Simioni, Dagher, & Fellows, 2012), and between PD
patients with and without ICDs while also comparing medication status (Claassen et al.,
2011). Simioni and colleagues (2012) tested PD patients and age-matched healthy adults
using the BART. They found that as the trials progressed, PD patients made significantly
riskier choices compared to controls. This finding parallels the observation of higher
prevalence of ICDs in PD patients compared to the general population (Ceravolo, Frosini,
Rossi, & Bonuccelli, 2010). The effect described by Simioni and colleagues (2012)
persisted at a 1.5-3 year follow-up study. Claassen and colleagues (2011) were interested
in whether PD patients with ICDs and without ICDs differed on BART performance on
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and off dopamine agonist medication. They found that on medication, the PD group with
ICD showed greater risk-taking (i.e., cognitive impulsivity) but this was not found for the
PD group. Further, dopamine agonists increased risk-taking in participants who were
taking higher doses compared to those taking lower dopamine doses. Taken together,
these findings suggest that the effect of dopamine agonists on cognitive impulsivity might
be dose-dependent and interact with other vulnerabilities of the dopaminergic system that
promote ICD behaviours.

1.4.1.2 Motor impulsivity
Motor impulsivity refers to the inability to withhold pre-potent and automatic responses
(Antonelli et al., 2011). A number of behavioural paradigms have been developed to
investigate response inhibition and motor impulsivity. One such paradigm is the Stop
Signal Task (SST; Logan, Van Zandt, Verbruggen, & Wagenmakers, 2014; Verbruggen
& Logan, 2008). The Stop Signal paradigm requires participants to respond as quickly as
possible to some stimulus/stimuli (Go trials). However, if they hear an auditory tone (the
Stop Signal), participants are asked to withhold the response (Stop trials). The Stop
Signal appears after a variable Stop Signal Delay (SSD) that is typically dynamically
adapted until participants are able to inhibit their responses with a 50% success rate. The
latency between the SSD and the mean reaction time on Go trials, or Stop Signal
Reaction Time (SSRT), is an estimate of the stop process that is activated by presentation
of the Stop Signal. A longer SSRT is interpreted as worse inhibitory ability whereas
shorter SSRT reflects better inhibition.
Studies that have used the SST to assess motor impulsivity in PD generally find that PD
patients show worse motor inhibition compared to older adult controls (Obeso,
Wilkinson, Casabona, et al., 2011; Obeso, Wilkinson, & Jahanshahi, 2011; but see
Vriend et al., 2015). Research groups who examine the effect of dopaminergic
medication on SST performance in PD patients have not observed medication effects
(Claassen et al., 2015; Obeso, Wilkinson, & Jahanshahi, 2011). However, an imaging
study by Ray Li, Yan, Sinha, and Lee (2008) revealed that activity in the caudate
correlated with shorter SSRTs (i.e., better inhibitory control). This suggests an influence
of the dopaminergic system on motor inhibition performance on the SSRT. Claassen and

18

colleagues (2015) compared PD patients with concurrent ICD and PD patients without
ICD on the SST. They found that the PD group with ICD had motor impulse control
abilities that were just as proficient as the non-ICD group, despite overwhelming
evidence that PD patients with ICDs have greater cognitive impulsivity (Claassen et al.,
2011; O’Sullivan et al., 2011; Simioni et al., 2012; Steeves et al., 2009; Wu et al., 2015).
This finding reinforces the important distinction between motor and cognitive
impulsivity.
Another simple behavioural paradigm that assesses motor impulsivity is the Go/No-go
task (Yang, Glizer, Vo, Seergobin, & MacDonald, 2016). The participant is presented
with a random series of Go and No-go stimuli. For the Go stimulus (e.g., ‘X’), the
participant is required to make a keypress response (e.g., press the spacebar). Conversely,
the participant is instructed to withhold any keypress responses for the No-go stimulus
(e.g., ‘K’). Participants are asked to make their responses as quickly and accurately as
possible. Importantly, the Go stimulus is presented at a much higher probability than the
No-go stimulus (e.g., 75% Go, 25% No-go), establishing ‘Go’ as the pre-potent
automatic response. As such, the number of No-go errors, which refers to trials for which
the participant was unable to suppress the Go response and erroneously responded to the
No-go stimulus, acts as a measure of motor impulsivity. Along a parallel line of
reasoning, the number of Go timeouts, which refers to the trials for which the participant
failed to make a Go response in time, corresponds to more conservative responding, or
less motor impulsivity. In summary, greater motor impulsivity can be observed as
increased No-go errors and/or decreased Go timeouts. Conversely, less motor impulsivity
corresponds with fewer No-go errors and/or more Go timeouts. Although the Go/No-go
paradigm is a rather simple task, it constitutes a good measure of motor impulsivity and is
easy for participants to comprehend. This is especially important when testing an elderly
clinical population.
In a study using the Go/No-go task in young healthy adults, Yang and colleagues (2016)
found that administration of pramipexole, a dopamine agonist, increased Go timeouts.
However, they did not observe the parallel observation of decreased No-go errors. The
researchers attributed this to the fewer number of No-go trials (i.e., 25% of trials) and
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thus less power in statistical analyses. Nonetheless, the presence of increased Go
Timeouts suggests that dopaminergic treatment results in more considered responding
(i.e., decreases motor impulsivity). Importantly, reaction times (RTs) were not different
between medication states, suggesting that the conservative responding was not due to
general slowing, sleepiness, or impaired motor ability. In the current study, we wanted to
extend the same task to a clinical PD sample and examine the effect of dopaminergic
medication.

1.4.2 Previous Go/No-go studies in PD
The Go/No-go paradigm has been employed to investigate motor impulsivity and
response inhibition in PD.

Most studies focused on differences between various

subgroups of PD (Cohen et al., 2014; Marzinzik et al., 2015; O’Callaghan, Naismith,
Hodges, Lewis, & Hornberger, 2013; Pessiglione et al., 2005; Peterson et al., 2015).
Other studies compared PD performance to that of healthy, age-matched controls
(Cooper, Sagar, Tidswell, & Jordan, 1994; Dujardin et al., 2013; Franz & Miller, 2002;
Nakashima, Shimoyama, & Takahashi, 1993). However, few studies have sought to
understand the effect of dopaminergic therapy on motor impulsivity in PD, contrasting
performance in the on and off dopaminergic states (Antonelli et al., 2014; Farid et al.,
2009; Herz et al., 2014). To this point, studies using the Go/No-go task to investigate
motor impulsivity in PD have generally failed to reveal significant group or on-off
differences (Antonelli et al., 2014; Farid et al., 2009; Herz et al., 2014), though most
included low numbers of participants and potentially were underpowered to detect
differences.

Further, the Go/No-go procedures in these studies often featured task

parameters that failed to clearly establish a pre-potent Go response either by having low
proportions of Go trials or multiple Go and No-go stimuli (Antonelli et al., 2014; Herz et
al., 2014). Consequently, to our knowledge, this represents the first study to implement a
straightforward Go/No-go paradigm in which clear Go responses were biased, and in
which the impact of dopaminergic therapy on PD patients was tested.
Geffe and colleagues (2016) used a variant of the Go/No-go task to assess implicit
learning in de novo untreated PD patients on versus off a single dose of L-dopa. In the
conditioning phase, a series of stimuli were presented such that one non-target prime
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stimulus acted as a reliable cue for presentation of the target stimulus in the subsequent
trial. During the conditioning phase, participants learned to anticipate that the target
stimulus would follow a particular non-target prime stimulus. Each conditioning phase
was followed by a deconditioning phase, during which non-target stimuli and the target
stimulus were presented randomly. PD patients off medication and healthy controls were
found to make more errors in the No-go condition of the deconditioning phase. This was
interpreted as evidence that associations between the prime stimulus and the target
stimulus had been learned in the conditioning phase.

This learning enhanced the

anticipation that the target stimulus would follow, leading to more No-go responses.
When PD patients were on medication, they evidenced fewer No-go errors in the
deconditioning phase. The authors interpreted this as evidence that association learning
between prime stimuli and target stimuli had been less well-learned by patients treated
with dopaminergic therapy. This finding is consistent with previous research showing
that dopaminergic therapy impairs learning (Cools, Barker, Sahakian, & Robbins, 2001;
Cools, Lewis, Clark, Barker, & Robbins, 2007; Gallant, Vo, Seergobin, & MacDonald,
2016; MacDonald et al., 2011; MacDonald & Monchi, 2011; Swainson et al., 2000;
Vaillancourt et al., 2013; Vo et al., 2014; Vo, Seergobin, & MacDonald, 2017).
However, the fact that PD patients performed fewer No-go responses on dopaminergic
therapy in the deconditioning phase could also be reflective of enhanced motor control.
Due to the design, either interpretation is possible. Geffe and colleagues (2016) used
their variant of the Go/No-go task to investigate implicit learning whereas the current
study is focused on motor impulsivity and inhibition. Our version of the Go/No-go task is
designed to establish a strong pre-potent Go response and accordingly acts as a measure
of motor inhibition.

1.5 Current study
Our goal in this study was to elucidate the effect of dopaminergic therapy on motor
impulsivity in PD. Toward this end, we tested PD patients on and off dopaminergic
medication with the Go/No-go paradigm. PD patients took their usual dopaminergic
therapy as prescribed by their treating neurologist in the ON Session. For the OFF
Session, PD patients refrained from their dopaminergic therapy for 12 to 20 hours as
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detailed in the Methods section. To our knowledge, this represents the first study to
implement a straightforward Go/No-go paradigm that clearly established the Go response
as the pre-potent response, in which the impact of dopaminergic therapy in PD patients
was directly tested with an on-off design.
Based on this previous research, here, we hypothesized that PD patients would evidence
more impulsive responding in the off state. We expected that dopaminergic therapy
would remedy motor impulsivity, resulting in more considered and cautious responding.
Again, impulsive responding was expected to be indexed by a) lower Go Timeout rate
and/or b) higher No-go Error rate. In contrast, more cautious and considered responding
would be expressed a) higher Go Timeout rate and/or b) lower No-go Error rate, as
described above.
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Chapter 2 : Methods
A version of this chapter has been published (Yang et al., 2018).

2.1 Participants
Twenty-seven PD patients (16 males, mean age 67.81 ± 8.64 years) were recruited from
the University of Western Ontario and Health Sciences North Hospital in Sudbury,
Ontario. Participants were pre-screened for inclusion and exclusion criteria. All PD
patients had been previously clinically diagnosed with PD by a licensed neurologist and
met the UK Brain Bank criteria for a diagnosis of PD (Hughes, Daniel, Kilford, & Lees,
1992). Participants were excluded for the following reasons: neurological disorders other
than PD (e.g., stroke, seizures, dementia, mild cognitive impairment), psychiatric
disorders other than mild-to-moderate depression [i.e., 29/63 > on Beck Depression
Inventory (BDI; (Aaron T Beck, Steer, & Brown, 1996))] or anxiety [i.e., 36/63 > on
Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988)], or history of
alcoholism or drug abuse. Further, PD patients were excluded if they were not treated
with dopaminergic therapy. Two patients were taking entacapone as an adjunct to Ldopa. One patient was taking both entacapone and amantadine as adjunctive therapies.
One patient was taking dopamine agonists alone as primary therapy. The remaining
patients were taking L-dopa as their primary therapy: either L-dopa alone (N = 15), or Ldopa in combination with dopamine agonists (N = 8). The data of participants who scored
below 24 on the Montreal Cognitive Assessment (MoCA) were excluded from analyses.
One PD patient was excluded for this reason. Finally, participants were excluded if their
mean RTs or error rates in the Go or No-go conditions fell outside 2.5 standard deviations
of the Group mean for that Medication Session (i.e., outliers). Four additional PD patients
were excluded for having data that were deemed outliers. Analyses were completed with
the data of the remaining 22 PD patients. This study was carried out in accordance with
the recommendations of the Health Sciences Research Ethics Boards of the University of
Western Ontario with written informed consent from all subjects. All subjects gave
written informed consent in accordance with the Declaration of Helsinki (World Medical
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Association, 2013). The protocol was approved by the Health Sciences Research Ethics
Boards of the University of Western Ontario (see Appendix A).

2.2 Apparatus
The Go/No-go task was conducted on a desktop computer (LG model 73821B-10) using
the Windows 7 Professional operating system and a 22.0” monitor (LG Flatron
W2242TQ) running on a resolution of 1600 x 900 pixels. Participants were seated
approximately 50 cm away from the screen and used a keyboard (Logitech K120) to
record their responses.

2.3 Procedures
All participants completed two testing sessions on consecutive days at the University of
Western Ontario or Health Sciences North Hospital. For the OFF Session, PD patients
were instructed to abstain from taking L-dopa/carbidopa and entacapone for 12-18 hours
before the start of the session, and dopamine agonists (e.g., pramipexole, ropinirole,
pergolide) as well as amantadine, rasagiline, and selegiline for 16-20 hours before the
start of the session. For the ON Session, PD patients were instructed to take all
dopaminergic medications for PD as prescribed by their treating neurologist. On-off order
was randomly assigned and counterbalanced. After the exclusion of five PD patients as
previously described, twelve participants had an on-off medication order and the
remaining ten participants had an off-on order. All participants were debriefed about the
details of the study once they completed the second session. Participants were
compensated for their time and participation.

2.3.1 Pre-task assessments
Demographic and clinical data [i.e., age, sex, education, years of education, handedness,
PD duration, Levodopa Equivalent Dose (LED)] were collected from all participants. PD
duration refers to the number of years since a diagnosis of PD. LED is a calculation of the
daily dose of dopaminergic therapy in units of L-dopa equivalents. Calculation of LED
(mg) for each PD patient was based on the theoretical L-dopa equivalence (Hiebert,
Seergobin, Vo, Ganjavi, & MacDonald, 2014; Wüllner et al., 2010) as follows: L-dopa
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dose (mg) x 1 + L-dopa controlled release (mg) x 0.75 + L-dopa x 0.33 if taking
entacapone + amantadine (mg) x 0.5 + bromocriptine (mg) x 10 + cabergoline (mg) x 50
+ pergolide (mg) x 100 + pramipexole (mg) x 67 + rasagiline (mg) x 100 + ropinirole
(mg) x 16.67 + selegiline (mg) x 10.22.
Heart rate (HR), systolic blood pressure (BP), and diastolic BP were measured using an
automated blood pressure monitor (Omron model BP785N) at the beginning and end of
each testing session. Participants were also given a self-reported visual analogue scale
(VAS; see Appendix B) at these two time-points to assess subjective alertness (Bond &
Lader, 1974).
To assess baseline cognitive functioning, PD patients completed general cognitive
assessments in the on state. These general cognitive assessments and questionnaires were
the American National Adult Reading Test (ANART; see Appendix C), MoCA (see
Appendix D), and Controlled Oral Word Association Test (COWAT; see Appendix E).
The ANART is a measure of verbal intelligence that has been adapted for use in North
America (Grober & Sliwinski, 1991). The MoCA is a validated cognitive screening tool
used to detect mild cognitive impairment (Nasreddine et al., 2005). The COWAT is used
to assess verbal and category fluency (Ross et al., 2007). Participants also completed the
Barratt Impulsiveness Scale (BIS; see Appendix F), Sensation Seeking Scale (SSS; see
Appendix G), Questionnaire for Impulsive-Compulsive Disorders in PD – Rating Scale
(QUIP-RS; see Appendix H), and New Freezing of Gait (NFOG; see Appendix I)
questionnaire. The BIS and SSS are validated questionnaires estimating trait
impulsiveness (Patton, Stanford, & Barratt, 1995) and sensation-seeking (Zuckerman,
Eysenck, & Eysenck, 1978), respectively. The QUIP-RS is a valid and reliable measure
of ICD symptom severity (Weintraub et al., 2012). The NFOG is a questionnaire used to
assess freezing of gait in PD (Giladi et al., 2000).
Additionally, all participants completed the BDI, BAI, and Starkstein Apathy Scale
(SAS; see Appendix J) in both sessions. The BDI, BAI, and SAS are commonly used
assessments of depression (Beck et al., 1996), anxiety (Beck et al., 1988), and apathy
(Starkstein et al., 1992) in PD populations. Motor function was assessed on both testing
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days using the Motor Subscale of the Unified PD Rating Scale (UPDRS; Goetz et al.,
2008; see Appendix K).

2.3.2 Go/No-go task
The Go/No-go paradigm is commonly used to assess motor impulsivity. The task consists
of Go trials and No-go trials. On Go trials, participants were asked to respond by making
a keypress as quickly as possible when the letter ‘X’, the visual Go signal, was
presented. On No-go trials, participants were instructed to withhold keypress responses,
when the letter ‘K’, the visual No-Go signal, was presented. On every trial, either the
letter ‘X’, the Go signal, or the letter ‘K’, the No-Go signal, appeared in the center of the
screen. Participants were instructed to press the spacebar for ‘X’ and avoid pressing any
keys for ‘K’. The visual stimuli were presented for a maximum of 750 milliseconds (ms),
or until participants responded with a keypress. A blank screen was presented for a
random duration between 400 and 800 ms during the inter-trial interval. See Figure 5 for
a schematic of the Go/No-go task. The letter ‘X’ was presented on 75% of trials, and the
letter ‘K’ was shown in the remaining 25% of trials, in a random order. This ratio of Go
to No-go trials was intended to establish the Go keypress as the pre-potent response.
Participants were instructed to make responses as quickly and accurately as possible. On
each testing day, participants completed a total of 256 trials, organized into 2 blocks of
128 trials each, with 10 second breaks at the midpoint of each block and for a slightly
longer break between the two blocks.
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Figure 5. Schematic of the Go/No-go task.
A blank screen was displayed for a random period between 400 and 800 ms as the inter-trial interval. Either
the Go stimulus (‘X’) or No-go stimulus (‘K’) was displayed for a maximum of 750 ms or until response.
For the Go stimulus, participants were required to press the spacebar as quickly and accurately as they
could. For the No-go stimulus, no response was required. The Go stimulus was presented 75% of the time
whereas the No-go stimulus was presented 25% of the time, establishing “Go” as the pre-potent response.

2.4 Data analysis
Physiological measures (i.e., HR, Systolic BP, Diastolic BP, and VAS Alertness) were
compared using 2 x 2 analyses of variance (ANOVAs), with Medication (on vs. off) and
Time (Pre-Task vs. Post-Task) as within-subject variables. Affective measures (i.e., mean
BDI, BAI, and SAS scores) were compared between on and off Medication states using
paired-samples two-tailed t-tests. The dependent measures for the Go/No-go task were a)
Go RT, comprising the mean RT for responses that occurred prior to the 750 ms deadline,
b) No-go Error RT, consisting of the mean RT for erroneous responses provided in the
No-go condition, c) Go Timeout Rate, reflecting the percentage of trials on which
participants failed to respond prior to the 750 ms deadline, and d) No-go Error Rate,
denoting the percentage of trials on which participants erroneously made a keypress
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response in the No-go condition. RTs were calculated as the time in ms between the onset
of the visual stimuli and the keypress responses. Data values for Go RTs were trimmed if
they fell more than 2.5 standard deviations from the mean Go RTs in each medication
state for each participant. The same process was used to trim No-go Error RT values.
Lower Go Timeout rates and higher No-go Error rates were indicative of greater motor
impulsivity whereas higher Go Timeout rates and lower No-go Error rates indexed less
impulsive responding. Go RTs and No-go Error RTs were analyzed using non-parametric
two-tailed Wilcoxon Signed Ranks Tests, and Go Timeout Rate and No-go Error Rate
were analyzed using paired-sample two-tailed t-tests, with Bonferroni correction for
multiple comparisons. Analyses were performed using Excel (Version 2016), IBM SPSS
Statistics (Version 21), and GraphPad Prism (Version 6). Data were considered
significant if p < 0.05.
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Chapter 3 : Results
A version of this chapter has been published (Yang et al., 2018).

3.1 Demographic, baseline screening cognitive, affective,
and physiological measures
Demographic and cognitive measures are presented for PD patients (see Table 1). All PD
patients were within 2.5 standard deviations of the group mean for the NFOG, BIS, SSS,
QUIP-RS ICD, QUIP-RS Total, MoCA, ANART, COWAT FAS, and COWAT Animal.
UPDRS scores were compared between on and off medication states using a pairedsamples two-tailed t-test. PD patients showed significantly higher UPDRS scores off
dopaminergic medication compared to on, which was expected (t(21) = 10.139, p <
0.001).
Physiological measures, including HR, Systolic BP, Diastolic BP, and VAS Alertness
were analyzed using 2 x 2 ANOVAs, with Medication (on vs. off) and Time (Pre-Task
vs. Post-Task) as within-subject variables. HR was significantly higher Pre-Task
compared to Post-Task (Figure 6 A; F(1,21) = 24.569, MSe = 31.507, p ≤ 0.001).
Additionally, Systolic BP was significantly higher off compared to on (Figure 6 B;
F(1,21) = 15.647, MSe = 88.459, p = 0.001). Diastolic BP showed a similar significant
effect of Medication, with significantly higher Diastolic BP off compared to on
dopaminergic therapy for PD patients (Figure 6 C; F(1,21) = 11.743, MSe = 36.046, p
=0.003). For VAS Alertness (Figure 6 D), no significant differences were found across
Medication and Time (p > 0.05).
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Variable
N
Age
Sex
Education
Handedness
PD duration
LED
UPDRS - ON
- OFF
NFOG
BIS
SSS
QUIP-RS ICD
QUIP-RS Total
MoCA
ANART
COWAT FAS
COWAT Animal

Value
22
66.77
11 males, 11 females
15.18
20 right, 2 left
5.23
626.59
17.43
21.82
t(21) = 10.139
7.86
59.23
11.59
13.05
24.91
27.32
122.72
15.71
21.23

SD
9.15
4.11
5.71
276.31
6.25
6.06
p < 0.001
7.52
8.99
4.74
8.62
14.70
1.73
6.46
5.22
6.93

Table 1. Demographic and cognitive measures.
Average demographic and cognitive measures for non-excluded PD patients. Values are presented as group
means ± SD unless otherwise listed. All values are in units of the respective questionnaire or task scale. N:
number of participants; Education (years): number of years of secondary and post-secondary education; PD
duration (years): number of years since PD diagnosis; LED (mg): Levodopa Equivalent Dose; UPDRS:
Motor Subscale Score of the Unified PD Rating Scale/56, listed for on and off medication; NFOG: New
Freezing of Gait Questionnaire/28; BIS: Barratt Impulsiveness Scale/120; SSS: Sensation-Seeking
Scale/40; QUIP-RS ICD: Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease Rating
Scale – Impulse-Control Disorders/64; QUIP-RS Total: Questionnaire for Impulsive-Compulsive Disorders
in Parkinson’s disease Rating Scale – Total score/112; MoCA: Montreal Cognitive Assessment/30;
ANART: American National Adult Reading Test/135.6; COWAT FAS (number of words): Controlled Oral
Word Association Test FAS Task; COWAT Animal (number of words): COWAT Animal Task. UPDRS
scores were significantly higher off medication (p < 0.001).
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Figure 6. Physiological measures.
Physiological measures for PD patients (N = 22). Values are presented as group means ± 95% confidence
interval as per Cousineau (2005). Data were analyzed using two-way ANOVAs. A) HR (beats per minute)
was significantly higher Pre-Task compared to Post-Task (*** p ≤ 0.001). B) Systolic BP (mmHg) was
significantly higher for the OFF Session compared to the ON Session (***). C) PD patients had
significantly higher diastolic BP (mmHg) off medication compared to on (***). D) No differences in VAS
Alertness were found across Time and Medication (p > 0.05).

Affective measures (BDI, BAI, and SAS) were compared between on and off medication
states using paired-samples two-tailed t-tests (Figure 7). For all affective measures, there
were no significant differences across Medication states (all p > 0.05).
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Figure 7. Affective measures.
Affective measures for PD patients (N = 22). Values are presented as group means ± 95% confidence
interval for repeated measures as per Cousineau (2005). Affective measures were analyzed using pairedsamples two-tailed t-tests. A) PD patients did not significantly differ on the BDI between on and off
medication states (p > 0.05). B) There was no significant effect of Medication state on the BAI (p > 0.05).
C) SAS score did not show a significant difference between on and off states (p > 0.05).

3.2 Go No-go task
We investigated the effect of Medication (on vs. off) on the dependent measures of mean
Go RT and No-go Error RT using two-tailed Wilcoxon Signed Ranks Tests, and Go
Timeout Rate and No-go Error Rate using paired-samples two-tailed t-tests in the Go/Nogo task using the Bonferroni correction. Mean Go RT was not significantly different for
PD patients on and off dopaminergic medication (Figure 8 A; p > 0.05). No significant
difference was found between on and off No-go mean RT (Figure 8 B; p > 0.05). PD
patients on medication had a significantly higher Go Timeout Rate compared to off
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dopaminergic therapy (Figure 8 C; t(21) = 2.851, p = 0.010) even after applying the
Bonferonni correction (i.e., α = 0.0125). Examining No-go Error Rate, there were no
significant effects of Medication (Figure 8 D; p > 0.05).
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Figure 8. Go/No-go task measures.
Dependent Go/No-go measures for PD patients (N = 22), on and off dopaminergic medication. Values are
presented as group means ± 95% confidence interval for repeated-measures as per Cousineau (2005). Go
RTs and No-go Error RTs were analyzed using non-parametric two-tailed Wilcoxon Signed Ranks Tests,
and Go Timeout Rate and No-go Error Rate were analyzed using paired-sample two-tailed t-tests, with the
Bonferroni correction for multiple comparisons. A) Mean Go RT was not significantly different for PD
patients on and off dopaminergic medication (p > 0.05). B) No-go Error RT did not show a significant
effect of Medication (p > 0.05). C) PD patients had a significantly higher Go Timeout Rate on
dopaminergic medication compared to off (** p = 0.010). D) No significant differences were found
between on and off medication for No-go Error Rate.
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Chapter 4 : Discussion
A version of subsections 4.1, 4.2, 4.4, 4.6, and 4.7 of this chapter has been published
(Yang et al., 2018).

4.1 Summary of results
We found that dopaminergic medication increased the Go Timeout rate in PD patients
compared to their performance off medication. In this way, dopaminergic therapy
reduced motor impulsivity, inducing a more conservative response pattern for PD
patients. We did not see a concomitant decrease in No-go errors for patients on relative to
off dopaminergic treatment, however. A lower No-go Error rate in the on state would also
signal decreased motor impulsivity in the No-go condition to parallel adoption of a more
considered response strategy in the Go condition producing more Go Timeouts. To
engender a pre-potent Go response, there were far fewer No-go trials relative to Go trials,
however. It is possible that the No-go condition did not have the statistical power to
reveal No-go error differences between on and off medication states. Although the effect
of dopaminergic medication on No-go errors did not reach significance, more Go
Timeouts when on medication corroborates the notion that dopaminergic treatment
causes more conservative responding. This is despite the fact that for PD patients,
dopaminergic therapy improves motor function and speeds movements overall. In
contradistinction to the widely-recognized enhancement of cognitive/motivational
impulsivity producing ICDs in PD, increased Go Timeouts in the ON Session suggests
that dopaminergic medications reduce motor impulsivity.
Comparisons of physiological measures showed that PD patients had lower HR post
relative to pre Go/No-go Task. This effect of lower HR was fully expected because
participants were sitting and inactive for the study period and had acclimatized to the
novelty of the setting. PD patients also had increased systolic and diastolic BP off relative
to on dopaminergic medication. This was anticipated as L-dopa is known to lower BP
(Noack, Schroeder, Heusser, & Lipp, 2014). Participants did not show any differences in
subjective alertness, BDI score, BAI score, or SAS score across ON-OFF Sessions,

34

demonstrating that our Go/No-go findings were not due to changes in alertness or mood
between the two medication states.

4.2 Effects of dopaminergic therapy on the Go/No-go task
There are few studies in the PD literature that have investigated motor impulsivity using
the Go/No-go in PD patients. Fewer still have investigated the effect of dopaminergic
therapy on performance though an important and concerning side effect of dopaminergic
therapy is disordered impulse control. Herz and colleagues (2014) compared Go/No-go
performance between PD patients with (N = 13) and without (N = 13) dyskinesia, and
healthy controls (N = 13), with both patient groups being tested on and off dopaminergic
medication. Herz and colleagues (2014) used a variant of the Go/No-go task that included
multiple Go responses (i.e., pressing either the left or right key) in addition to the No-go
response. They did not find a modulation of Go/No-go performance by dopaminergic
treatment. The added complexity related to multiple Go responses potentially reduced the
pre-potency of Go relative to No-go, resulting in less difficulty withholding responses in
the No-go condition. In another study, Farid and colleagues (2009) compared Go/No-go
performance of PD patients (N = 9) on and off medication relative to healthy controls (N
= 9) who performed the task only once. They did not find behavioral differences between
patients ON versus OFF medication, or relative to performance of healthy older controls
on Go/No-go accuracy or RT. However, with only nine participants in each group, the
study likely was underpowered statistically to detect true differences if they occurred.
Further, medication order was not counterbalanced. PD patients were always assessed in
the OFF-ON order. In this way, and because healthy controls only performed the task
once, order effects were confounded with medication effects. Antonelli and colleagues
(2014) contrasted Go/No-go performance of PD patients (N = 7) on and off the dopamine
agonist pramipexole. They found that administration of pramipexole increased impulsive
choices on a delayed discounting task ─ their measure of cognitive impulsivity. However,
no on-off differences were observed on Go/No-go performance ─ their measure of motor
impulsivity. This study was important in providing evidence that dopaminergic treatment
affects distinct forms of impulsivity dissimilarly, supporting the idea that impulsivity is
not a unitary concept, but rather is multifaceted. These results must be viewed with
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caution, however, considering that due to a sample size of only seven PD patients, this
study was likely entirely underpowered. Further, the authors’ rendition of the Go/No-go
task involved presenting Go signals at 60%, and No-go signals at 40%, limiting the prepotency of the Go response.
In the single occasion to our knowledge when on-off differences have been observed,
these effects are not interpreted with respect to the effects of dopaminergic therapy on
motor impulsivity or the ability to withhold pre-potent responses. Geffe and colleagues
(2016) tested a version of the Go/No-go task in PD patients on and off dopaminergic
therapy though they included an implicit learning component to their study which was in
fact the focus (Geffe et al., 2016). Geffe and colleagues’ variant of the Go/No-go task
involved a conditioning phase during which participants were presented with a series of
stimuli consisting of one of three non-target cues or a target stimulus, such that one cue
consistently predicted subsequent target presentation in the following trial. In the Go
block, participants were instructed to make a keypress in response to the target stimulus.
In the No-go block, participants were required to make keypress responses to all nontarget cues and inhibit the keypress response for target stimuli. In addition, they had a
deconditioning phase during which no particular non-target cue predicted the target
stimulus. Geffe and colleagues found that for the No-go condition, PD patients off
medication and healthy controls showed increased errors in the deconditioning phase,
which was interpreted as evidence of implicit learning in the conditioning period.
However, this increase in error rate was not observed for PD patients when on
medication, which they interpreted as an impairment in implicit learning with the
addition of dopaminergic medication. Given that dopaminergic therapy is known to
adversely impact association learning, this interpretation is highly plausible. These effects
could also be interpreted as evidence that dopaminergic therapy reduces impulsive
responding (i.e., lower No-go error rate on relative to off dopaminergic therapy). This
latter account was not articulated by the researchers but remains a possible
reinterpretation. Overall, due to the many differences between the Go/No-go task used by
Geffe and colleagues (i.e., conditioning and deconditioning phases, blocked design of Go
and No-go trials, four stimuli of which one is the target stimulus), straightforward
inferences regarding the effect of dopaminergic therapy on motor impulse control were
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precluded. There were substantial differences in task parameters and research goals
between Geffe and colleague’s (2016) study and ours. However, their results are not at
odds with our findings. Consequently, to our knowledge, this represents the first study to
implement a straightforward Go/No-go paradigm in which clear Go responses were
biased, and in which the impact of dopaminergic therapy on motor impulsivity in PD
patients was unambiguously tested.

4.3 Go/No-go performance in PD subgroups
The Go/No-go paradigm has been employed to investigate impulsivity and response
inhibition in various subgroups of PD (Cohen et al., 2014; Marzinzik et al., 2015;
O’Callaghan et al., 2013; Peterson et al., 2015). In a study investigating inhibition and
dementia in PD, O’Callaghan and colleagues (2013) compared Go/No-go performance of
PD patients (n = 25), PD with frontotemporal dementia (n = 11), and older controls (n =
15). The PD group with frontotemporal dementia conducted more No-go errors (i.e.,
more motor impulsivity) than the PD group, which in turn made more No-go errors than
controls. Using neuroimaging, the authors provide evidence that frontostriatal atrophy
might contribute to motor impulsivity in PD. Cohen and colleagues (2014) conducted a
study contrasting PD patients (n = 13), PD patients with freezing of gait (n = 15), and
older controls (n = 16). PD patients with freezing of gait were observed making more Go
Timeouts (i.e., less motor impulsivity) than PD patients, suggesting differential motor
inhibitory abilities depending on freezing of gait status. In another study of motor
impulse control and freezing of gait, Peterson and colleagues (2015) contrasted PD
patients with (n = 13) and without (n = 12) freezing of gait using a Go/No-go task.
Participants were also fitted with inertial sensors to assess gait metrics during normal
walking and dual-task walking, for which participants completed a concurrent simple
behavioural task. The researchers found that Go/No-go performance was correlated with
dual-task interference for only the PD group with freezing of gait, suggesting a link
between impaired motor inhibition and freezing of gait in PD. Marzinzik and colleagues
(2015) examined PD patients with mild (n = 11) and advanced (n = 11) motor symptoms,
PD patients with dementia (n = 11), Alzheimer’s patients (n = 11), and healthy older
controls (n = 11) on a cued Go/No-go task. PD patients with advanced motor symptoms
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and dementia committed more Go Timeouts than controls, but the PD with dementia
group also committed more No-go errors than controls. In the PD group with dementia,
task performance was low and correlated with disease severity. The authors concluded
that deficits in PD dementia develop from dysfunctional inhibitory abilities.
Findings from these studies suggest that different subgroups of PD patients such as those
with freezing of gait or dementia might have altered motor impulse control as assessed by
the Go/No-go task. The current study did not separate PD patients by freezing of gait
status, and the PD participants tested did not have current or history of dementia. Our
specific aim in this study was to investigate the effect of dopaminergic medication on
motor impulsivity in a sample of non-demented PD patients. Future investigations of
motor impulsivity using the Go/No-go task could expand on the differences in motor
inhibition between subgroups of PD.

4.4 Other tasks of response inhibition
Consistent with the notion advanced here that dopaminergic treatment in fact increases
motor impulse control, Hiebert and colleagues (2014) found that PD patients evidenced
greater facilitation in the congruent condition of a modified Stroop task when tested off
dopaminergic therapy relative to the degree of facilitation observed in healthy agematched controls. Facilitation was normalized when PD patients were tested on their
usual dopaminergic therapy. We surmised that enhanced facilitation in the off state arose
due to more impulsive and less considered responding, which was rectified by usual
dopaminergic therapy. The current study and those presented above highlight the fact that
dopaminergic treatment has varied effects on different aspects of impulsivity. These
studies present evidence that dopaminergic therapy reduces motor impulsivity in contrast
to the more widely-understood effect of increasing cognitive/motivational impulsivity
producing ICDs in PD patients. This understanding is important for the clinical approach
to PD and decisions regarding titration of dopaminergic therapy considering motor as
well as cognitive symptoms.
Although SST studies investigating the effect of dopaminergic medication on motor
impulsivity have not shown effects of medication on SST performance in PD (Claassen et
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al., 2015; Obeso, Wilkinson, & Jahanshahi, 2011), neuroimaging has linked motor
impulse control on the SST to caudate activity (Ray Li et al., 2008). Further, the version
of the SST used by Obeso, Wilkinson, and Jahanshahi (2011) was a conditional SST
involving interleaved ‘critical’ and ‘non-critical’ trials, denoted by direction of the
stimulus. For ‘critical’ trials, participants were asked to stop their responses if they heard
the auditory Stop Signal. For ‘non-critical’ trials, participants were to ignore the Stop
Signal and complete the response. The interleaved nature of the trials introduces the
additional factor of conflict resolution, which potentially acted as a confound in their
study. Claassen and colleagues (2015) employed a traditional SST paradigm without
multiple conditions. They contrasted SST performance of 12 PD patients with ICD(s) on
and off dopaminergic medication, 12 PD patients without ICD on and off medication, and
12 matched healthy controls. With 12 participants in each group, it is entirely possible
that the study was underpowered to discover potential medication effects. The current
study aimed to address the common issue of small sample size in motor inhibition studies
in PD by testing a total of 27 PD patients.
Our observations in this study are in accordance with previous research on response
inhibition and/or response withholding in PD generally. In a meta-analysis of the effects
of dopaminergic medication and PD disease duration on measures of response inhibition,
Manza and colleagues (2017) found that for studies of response inhibition with PD
participants on dopaminergic medication, response inhibition deficits were significantly
correlated with disease duration. The authors examined studies of common measures of
response inhibition, including the anti-saccade, Stop Signal, Stroop, and Go/No-go tasks.
PD patients were found to have poorer response inhibition compared to matched healthy
controls, in agreement with conclusions from another previous meta-analysis (Kudlicka,
Clare, & Hindle, 2011). For studies with PD patients at earlier disease stages (i.e., < than
7 years since diagnosis), dopaminergic medication tended to improve the ability to inhibit
inappropriate responses, resulting in performance that was worse than but approached the
level of healthy controls (Manza et al., 2017). Conversely, studies with PD patients at
later disease stages (i.e., > than 7 years since diagnosis) tended to find that dopaminergic
medication worsened response inhibition compared to the unmedicated state. The current
study investigated PD patients with an average disease duration of approximately five
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years (range 1-26 years), comparable to the patient samples in the studies examined by
Manza and colleagues (2017) in their meta-analysis of PD patients at earlier disease
stages. Our finding that dopaminergic therapy caused PD patients to enact more cautious
responding, yielding more Go Timeouts, is entirely in line with the overall observation in
the PD literature that dopaminergic therapy improves inhibition of inappropriate motor
responses in PD.

4.5 Mechanisms of impulsivity
4.5.1 Cognitive impulsivity
Several neurophysiological mechanisms have been proposed to explain the link between
dopaminergic medication and increased cognitive impulsivity. First, as previously
described, dopaminergic treatment is known to impair response learning (Foerde &
Shohamy, 2011; MacDonald & Monchi, 2011). Impaired ability to learn from negative
consequences or loss could contribute to increased risk-taking (Claassen et al., 2011).
The increase in tonic dopamine levels in response to dopaminergic therapy might
mitigate the gaps in phasic dopamine activity corresponding to lack of reward or a
negative consequence (Cools et al., 2001; Guthrie, Myers, & Gluck, 2009; van Eimeren
et al., 2010). Next, dopaminergic treatment has been suggested to increase response to
rewarding stimuli (Claassen et al., 2011). Increased tonic dopamine signaling in the VS
(especially the NAcc) could amplify the bursts of dopamine activity corresponding to
rewards (Cools et al., 2001). This interpretation could also be caused by increased
attentional focus on rewarding experiences, or amplified downstream subjective appraisal
of rewarding stimuli (Cools et al., 2001; Voon, Reynolds, et al., 2010). Lastly, an
alternative account suggests that chronic dopaminergic treatment results in a blunted
response to rewards, leading to increased reward-seeking to compensate for the
dampened sensation of reward (Riba, Krämer, Heldmann, Richter, & Münte, 2008).
Consistent with this explanation, PD patients with ICDs have been shown to have lower
DAT density in the VS compared to non-ICD PD patients (Cilia et al., 2010; Cilia & van
Eimeren, 2011). Less dopamine synaptic clearance by DAT decreases the dopamine
receptor availability for phasic responses to rewarding stimuli (Cilia et al., 2010; Mata,
Hau, Papassotiropoulos, & Hertwig, 2012). It is unclear which one of these explanations
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best accounts for dopamine-related increased cognitive impulsivity and subsequent ICD
development; all three explanations likely contribute to this phenomenon. Additional
theoretical framing is required to combine these different interpretations into a single
explanatory model.

4.5.2 Motor impulsivity
Neuroimaging has linked motor impulsivity with activation in the DS, especially in the
caudate (Ray Li et al., 2008; Zandbelt & Vink, 2010). The mechanism for improved
motor impulse control with dopaminergic

therapy is likely linked to the

neurophysiological properties of the many dense MSNs in the DS (Wickens et al., 2007;
Zhang et al., 2009). Dopamine stimulation results in rapid maximal responses in the DS,
leading to enhanced signaling of motor impulse control related processes. Because the
DS tends to mediate binary response patterns (i.e., engage or suppress), it does not appear
to be susceptible to overdosing effects. No studies to date have demonstrated overdosing
of the DS; administration of dopaminergic treatment seems to simply increase DSmediated cognitive functions. This explains the observation of increased motor impulse
control with dopaminergic medication in young healthy adults (Yang et al., 2016), who
presumably have normal dopamine production at baseline.
The notion of motor impulse control being mediated by DS activity is entirely consistent
with our findings in the present study. When PD patients are off medication, the SNc is
unable to supply sufficient dopamine to the DS. Lower motor impulse control abilities
manifest as greater motor impulsivity on a motor inhibition task such as the Go/No-go
task. When the patients remediate dopamine-deficiency in the DS using dopaminergic
medication, motor impulse control is improved, leading to more conservative responding
(i.e., increased Go Timeouts) on the Go/No-go task.

4.6 Effects of dopaminergic therapy on cognition
It is now understood that dopaminergic treatment in PD leads to improvements in some
aspects of cognition, but impairments in others (Cools et al., 2001; MacDonald et al.,
2011; MacDonald & Monchi, 2011; Rowe et al., 2008). These complex cognitive effects
are explained by differences in dopaminergic levels at baseline across different brain
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regions in PD. According to this view, dopaminergic therapy is titrated to a dose needed
to replenish the dopamine-deficient DS and improve movement symptoms in PD.
Dopaminergic therapy distributes in a non-targeted fashion, however, overdosing regions
such as the VS and medial prefrontal regions that are at baseline dopamine-replete,
innervated by the relatively-spared VTA (Cools, 2006; Cools et al., 2001; Gotham et al.,
1986, 1988; Swainson et al., 2000; Vaillancourt et al., 2013). As a result, DS-mediated
cognitive functions such as selective attention (Baunez & Robbins, 1999; de Manzano et
al., 2013; MacDonald et al., 2011), decision-making (Balleine, Delgado, & Hikosaka,
2007; Hiebert, Vo, et al., 2014; MacDonald et al., 2011), response inhibition (MacDonald
& Monchi, 2011; Wylie et al., 2012; Zandbelt & Vink, 2010), and overriding pre-potent
and automatic responses to enact more considered and accurate responding (Ali, Green,
Kherif, Devlin, & Price, 2009; MacDonald et al., 2014; MacDonald et al., 2011;
Robertson, Hiebert, Seergobin, Owen, & MacDonald, 2015) show improvements with the
addition of dopaminergic treatment. This is entirely in line with our findings here in the
Go/No-go task. In contrast, cognitive functions mediated by brain regions receiving
dopamine from VTA such as reward processing and feedback learning (Cools et al.,
2001, 2007; Gallant et al., 2016; MacDonald & Monchi, 2011; MacDonald et al., 2013;
Swainson et al., 2000; Vaillancourt et al., 2013; Vo et al., 2014; Vo et al., 2017),
motivation (Humphries & Prescott, 2010; MacDonald & Monchi, 2011; Simões-Franklin,
Hester, Shpaner, Foxe, & Garavan, 2010), and orienting (Anderson et al., 2016; Esslinger
et al., 2013; Jensen et al., 2007; MacDonald & Monchi, 2011; Zink, Pagnoni, Martin,
Dhamala, & Berns, 2003) are impaired.
Both our findings in the Go/No-go task, clarifying the effect of dopaminergic therapy on
motor impulsivity in PD, and the effects of dopaminergic medication on
cognitive/motivational impulsivity producing ICDs can be understood through the
framework provided above. DS has been implicated in limiting motor impulsivity by
ensuring more considered and less habitual responding (Cools, Rogers, Barker, &
Robbins, 2010; Djamshidian, O’Sullivan, Lees, & Averbeck, 2011; Hood et al., 2007;
MacDonald et al., 2011; Ness & Beste, 2013; Robertson et al., 2015). In contrast, VTAinnervated brain regions such as VS and orbitofrontal cortex mediate motivation and
reward processing (Balleine et al., 2007; Drijgers et al., 2012; Rowe et al., 2008). In PD,
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dopaminergic therapy normalizes DS dopamine deficiency and therefore predictably
improves the ability to make deliberate and less impulsive responses as we see here
(Balleine et al., 2007; Drijgers et al., 2012; Rowe et al., 2008). Conversely, treatment
with dopaminergic agents overdoses VS and other VTA-innervated brain areas,
dysregulating motivation and impairing reward processing, leading to ICDs. Our findings
and the literature linking ICDs to dopaminergic therapy are easily reconciled,
understanding that impulsivity is a multifaceted concept, with its various forms mediated
by distinct brain regions that are differentially dopamine-depleted in PD and hence
dissimilarly affected by dopaminergic therapy.

4.7 Limitations
By not presenting baseline PD performance relative to that of controls, we have not
established abnormal control of motor responses (i.e., motor impulsivity) in the PD
patients in our study. This was not our aim, though, as detailed above, reviews of this
literature confirm that PD patients consistently exhibit deficits in inhibition of pre-potent
responses and motor impulsivity (Kudlicka et al., 2011; Manza et al., 2017). Our
objective was to explicitly investigate, in back-to-back tests within PD patients, the effect
of dopaminergic therapy on motor impulse control using an accepted measure of this
process (i.e., Go/No-go; Antonelli et al., 2014; Hamidovic, Kang, & de Wit, 2008; Rubia
et al., 2001). Here, in PD patients, we entirely replicated the pattern that we observed in
healthy young controls (Yang et al., 2016). Specifically, we previously showed that
dopaminergic therapy increases the Go Timeout rate in healthy young controls. We
previously interpreted this pattern of results, as we have here, as evidence that
dopaminergic therapy increases control over motor responses and decreases the tendency
to make more impulsive responses (Yang et al., 2016).
The alternative explanation that dopaminergic therapy simply slowed cognitive processes
and/or motor execution rather than specifically promoting a more conservative response
pattern is contradicted by other measures in our study, in addition to well-studied,
established effects of dopaminergic therapy on behavior in the wider PD literature.
Dopaminergic therapy did not affect overall RTs in our PD patients and it significantly
speeded motor responses assessed with the UPDRS. Addressing bradykinesia and
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increasing the speed and fluency of movements and motor responses is the chief
beneficial effect of dopaminergic therapy in PD (Espay et al., 2011; Macerollo et al.,
2016). There is little evidence to suggest that dopaminergic therapy generally slows
cognitive processes and in fact there is support that it hastens them (Cools et al., 2001;
Hanna-Pladdy, Pahwa, & Lyons, 2015; Hood et al., 2007; MacDonald et al., 2011;
MacDonald & Monchi, 2011; Righi, Viggiano, Paganini, Ramat, & Marini, 2007; Shook,
Franz, Higginson, Wheelock, & Sigvardt, 2005). In contrast, dopaminergic therapy has
been shown to increase response inhibition abilities as well as to promote the adoption of
a more conservative response criterion, consistent with our explanation for increased Go
Timeouts in the on state for PD patients in our study.
It was also not possible for PD patients to be blinded to their medication status during the
on-off manipulation in our study. This is because patients had to comply with particular
instructions to take or abstain from their usual dopaminergic therapy in a certain manner
for on and off session, respectively. Even if these instructions could be concealed,
patients are well acquainted with their symptoms both on and off dopaminergic therapy
which precluded blinding patients to our medication manipulation. Consequently, we
cannot rule out the possibility that expectancy effects contributed to our results. However,
as previously noted, dopaminergic medications are known to speed motor functions in
PD patients (Espay et al., 2011) and consequently any expectancy effects would have
acted contrarily to the results that we obtained. Overall, despite these acknowledged
alternative interpretations, we interpret enhanced Go Timeout responses in the on state as
evidence that dopaminergic therapy reduces motor impulsivity. This account for our
findings is supported by a larger literature as detailed in the sections above.
Our finding of more Go Timeouts with the administration of dopaminergic therapy could
alternatively be interpreted as a worsening of ability to orient to stimuli. Lesion and
neuroimaging studies have linked orienting to stimuli with the VS (see MacDonald &
Monchi, 2011 for a review). A reinterpretation of our results in response to dopaminergic
treatment as poorer ability to orient to stimuli, which is presumably a VS-mediated
function, is entirely consistent with the patterns described by the dopamine overdose
hypothesis (Anderson et al., 2016; Esslinger et al., 2013; Jensen et al., 2007; MacDonald
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& Monchi, 2011; Zink et al., 2003). Here, we explain our finding of increased Go
Timeouts with the addition of dopaminergic treatment as decreased motor impulsivity
because the Go/No-go task has largely been interpreted in the context of response
inhibition and motor impulse control (Antonelli et al., 2014; Ballanger et al., 2009;
Fillmore, 2003; Liddle, Kiehl, & Smith, 2001; Rubia et al., 2001). However, we are not
able to fully rule out the possibility of an effect of dopaminergic treatment on the ability
to orient to stimuli.
Another limitation of the current study was that we did not conduct functional
neuroimaging despite interpreting our behavioural results with respect to changes in
activity in different brain areas. Our conclusions are supported by the wider literature
implicating the DS in motor impulse control (Ray Li et al., 2008; Zandbelt & Vink, 2010)
as well as imaging studies that show improvements in DS-mediated cognitive functions
with the addition of dopaminergic therapy (Ali et al., 2009; MacDonald et al., 2014;
MacDonald et al., 2011; Robertson et al., 2015; Zandbelt & Vink, 2010). However, the
interpretation of our behavioural results would have been further strengthened with the
use of functional neuroimaging to demonstrate the changes that occur in SNc- and VTAinnervated brain regions on and off dopaminergic therapy. Future investigations could
incorporate functional MRI and an MRI-compatible version of the Go/No-go task.

4.8 Conclusions
Overall, the results of this study lend support for the role of dopaminergic therapy in
decreasing motor impulsivity in PD. Our findings emphasize that impulsivity should be
addressed as a multi-faceted construct rather than a single concept. We also highlight the
importance of examining non-motor functions affected by dopaminergic medication in
PD. These findings improve our understanding of how dopaminergic therapy affects
cognition in PD. This knowledge will ultimately aid clinicians in developing optimal
dopaminergic medication regimens for their PD patients, taking into account the different
impacts on cognitive as well as motor functioning.
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Appendix H. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's
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Appendix I. New Freezing of Gait Questionnaire (NFOG).
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Appendix J. Starkstein Apathy Scale (SAS).
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Appendix K. Unified PD Rating Scale - Motor Subscale (UPDRS).
UPDRS Protocol
Ask at the start “which arm/hand do you have most difficulty with?”
Always start with LESS impaired side
Only model for a few seconds, then stop
“This is subject (PD/CTRL #), session #, (on/off) medication.”
1. Film face at rest for a few seconds
2. Ask patient to speak one-two sentences (for dysarthria)
•

“Today is a very nice day outside”

•

“I am at the University for an experiment”

3. Evaluate resting tremor
a. hands relaxed on thighs
b. with cognitive stressing “Close your eyes and name the months of the year
backward from December”
4. Evaluate tone
a. Bilateral upper extremities
5. Evaluate postural tremor
a. hands outstretched
b. fingertips apposed (forming wings with arms ensuring fingers are not touching)
6. Evaluate action tremor
a. Finger-to-nose (finger target should be arms-length away and in same position)
7. Evaluate bradykinesia
a. Finger taps (pinching) “Big and fast”
b. Hand opening-closing movements “Big and fast”
c. Pronation-supination movements “Fast as you can”
d. Toe-tapping (minimum 3 inches off ground)
8. Ask patient to rise from the chair without the assistance of his/her arms (arms crossed
over chest) “Fold your arms across and chest and stand up”
9. Evaluate gait, ask to walk up and down hallway 2-3 times, with turns
10. Pull test “Try to maintain your balance and limit yourself to one step backwards”

85

Curriculum Vitae

Name:

Xue Qing Yang

Post-secondary
Education and
Degrees:

Western University
London, Ontario, Canada
Master of Science
Department of Psychology
Cognitive, Developmental and Brain Sciences
2016 – Present
Western University
London, Ontario, Canada
Bachelor of Medical Science
Department of Physiology and Pharmacology
Honours Specialization in Physiology, Minor in Psychology
2012 – 2016

Honours and
Awards:

Canada Graduate Scholarship – Master’s Program
Canadian Institutes of Health Research
2017 – 2018
Ontario Graduate Scholarship (Offered)
2017
Undergraduate Student Research Award
Natural Sciences and Engineering Research Council of Canada
(NSERC)
2015
Continuing Admission Scholarship
Western University
2012 – 2016

Presentations

Clinical Neurological Sciences Departmental Research Day
Effects of Dopaminergic therapy on delay and probability
discounting in Parkinson’s disease
Poster presentation
2017
Retiring with Strong Minds Community Seminar
Different forms of impulsivity in Parkinson’s disease
Seminar presentation
2017

86

Research
Experience

Master’s degree
MacDonald Lab, Western University
Investigating the effects of Dopaminergic therapy on motor
planning and motor control in Parkinson’s disease
2016 – 2018
Master’s degree
MacDonald Lab, Western University
Dopaminergic therapy increases Go Timeouts in the Go/No-Go
task in patients with Parkinson’s Disease
2016 – 2018
Fourth year undergraduate thesis project
MacDonald Lab, Western University
Effect of pramipexole on motor impulsivity in young healthy
volunteers
2015 – 2016
NSERC Undergraduate Student Research Award
Peng Lab, York University
Role of Nodal and Versican in migration and invasion of epithelial
ovarian cancer cells
2015
Research Assistant
Neff Lab, Western University
Relationship between testosterone and immunity in bluegill sunfish
2014 – 2015

Related Work

Teaching Assistant
Psychology 2043A
Exceptional Children: Developmental Disorders
2018
Teaching Assistant
Psychology 1000
Introduction to Psychology
2016 – 2017

Publications:
Yang, X. Q., Glizer, D., Vo, A., Seergobin, K. N., & MacDonald, P. A. (2016).
Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers.
Frontiers in Human Neuroscience, 10, 523. https://doi.org/10.3389/fnhum.2016.00523

87

Yang, X. Q., Lauzon, B., Seergobin, K. N., & MacDonald, P. A. (2018). Dopaminergic
Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson’s
Disease. Frontiers in Human Neuroscience, 11, 642.
https://doi.org/10.3389/fnhum.2017.00642

